Cardiogenesis (CGCP) Listing Upgraded to New OTCQB(TM) Market for All U.S. Registered and Reporting OTC Securities
IRVINE, Calif., June 22 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (OTCQB: CGCP) today announced that its shares are now being quoted on the newly launched OTCQB™ market. Launched in April 2010, the OTCQB is a new market tier for OTC-traded U.S. companies that are registered and reporting with the Securities and Exchange Commission (SEC). As a result of Cardiogenesis' OTCQB designation, investors can now view real-time stock quotes with market depth (level 2). Listings may be found at http://www.otcmarkets.com .
"We are pleased to be listed on the OTCQB Market, a platform which provides increased trading transparency and efficiency, for our shareholders and potential investors," said Paul McCormick, Executive Chairman. "We believe that listing on this higher OTC tier will provide improved liquidity in our shares and is another step towards our future goal of listing on a national exchange."
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patien